Artivion (NYSE:AORT) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Artivion (NYSE:AORT) posted its earnings results on Thursday. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.14, FiscalAI reports. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The business had revenue of $123.79 million for the quarter, compared to analyst estimates of $120.97 million.

Here are the key takeaways from Artivion’s conference call:

• Third-quarter revenue grew 9% year over year in constant currency, led by 12% growth in stent grafts and 13% growth in On-X valves. Management said On-X supply has improved after manufacturing investments, while acknowledging that adjusted EBITDA fell 8% and gross margin declined.
• Artivion narrowed its 2026 outlook to 8%–10% adjusted constant-currency revenue growth and $93 million–$98 million of adjusted EBITDA. Management cited a Q4 currency headwind and an expected reversal of unusually strong preservation-services revenue; it also forecast PerClot’s departure to reduce 2027 revenue growth by about 2 percentage points and EBITDA growth by 4 points.
• AMDS implants increased following U.S. PMA approval, but starter-set sales remain slow because hospitals face administrative hurdles around the roughly $100,000 upfront purchase. Management said it is working to ease those barriers, but expects account adoption to take time.
• NEXUS preparations are progressing toward a planned U.S. launch on January 1, 2027, with surgeon interest, training, inventory-building, and sales-team expansion underway. Management expects sales to ramp gradually through 2027 and anticipates the combined business will be EBITDA-neutral for the year.
• The ARTIZEN trial for the Arcevo LSA platform has enrolled 56 patients, with enrollment completion expected in mid-2027. Management expects to present initial results from the first 30 patients and, if the trial succeeds, anticipates FDA approval in 2029.

Artivion Stock Down 20.1%

Shares of AORT stock traded down $5.09 during trading hours on Friday, hitting $20.23. 3,246,962 shares of the company were exchanged, compared to its average volume of 486,118. The stock has a market capitalization of $986.66 million, a price-to-earnings ratio of -56.21 and a beta of 1.31. The business’s 50-day simple moving average is $23.55 and its two-hundred day simple moving average is $28.98. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. Artivion has a one year low of $19.16 and a one year high of $48.25.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analysts’ estimates of about $121 million. The company also reported non-GAAP EPS of $0.08, above a consensus estimate of a $0.06 loss cited in one report. Artivion Q3 results
• Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential future growth catalysts. Revenue outlook and NEXUS launch
• Neutral Sentiment: Citizens JMP lowered its price target to $42 from $48 but maintained a Market Outperform rating; the revised target still implies substantial upside from the cited share price. Citizens JMP recommendations
• Negative Sentiment: Canaccord also cut its target, to $30, adding to concerns about analysts’ reassessment of the stock’s outlook. Canaccord price-target change
• Negative Sentiment: Despite revenue growth, Artivion posted a $7.9 million GAAP net loss, and adjusted EBITDA fell 8% to $22.5 million. Zacks also reported that the $0.08 quarterly EPS missed its $0.11 estimate, highlighting that earnings expectations vary by source and may weigh on sentiment. Zacks earnings analysis

Insider Activity

In related news, SVP Jean Holloway sold 977 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the sale, the senior vice president owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO James Mackin sold 70,000 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the sale, the chief executive officer directly owned 877,275 shares in the company, valued at approximately $25,397,111.25. This trade represents a 7.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 90,460 shares of company stock valued at $2,557,366. 6.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AORT. Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Jefferies Financial Group began coverage on shares of Artivion in a research note on Tuesday, October 20th. They set a “buy” rating and a $31.00 target price for the company. Weiss Ratings lowered shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Citizens Jmp cut their price target on Artivion from $48.00 to $42.00 and set a “market outperform” rating for the company in a research note on Friday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $44.00 target price on shares of Artivion in a report on Monday, July 20th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.00.

About Artivion

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.